Table 4.

Effect of varying ligand splitter and spacer length on TTR^a siRNA^b conjugate activity

Compound	Structure	% KDc day 7	% KDc day 14
11		90 ± 3	79 ± 4
6		93 ± 1	89 ± 3
12		91 ± 1	83 ± 3
13		86 ± 3	76 ± 4
14		88 ± 3	77 ± 4

All data shown as mean ± SEM.

^aTransthyretin

^bSmall interfering ribonucleic acid

^cPercent reduction (knockdown) of TTR protein in plasma at indicated time point after 2 mg/mL subcutaneous injection in C57BL/6 female mice aged 6–8 weeks (n = 4 per group)